RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Cyclacel Pharmaceuticals Stock

Cyclacel Pharmaceuticals Stocks 2024

Cyclacel Pharmaceuticals Stocks

850,820

Ticker

CYCC

ISIN

US23254L6039

WKN

A2P26W

In 2024, Cyclacel Pharmaceuticals had 850,820 outstanding stocks, a 0% change from the 850,820 stocks in the previous year.

The Cyclacel Pharmaceuticals Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2029e0.85
2028e0.85
2027e0.85
2026e0.85
2025e0.85
2024e0.85
20230.85
202211.26
20218.93
20203.63
20190.82
20180.6
20170.38
20163.42
20150.14
20140.09
20130.06
20120.03
20110.36
20100.02
20090.01
20080.01
20070.01
20060.01
2005-
2004-

Cyclacel Pharmaceuticals shares outstanding

The number of shares was Cyclacel Pharmaceuticals in 2023 — This indicates how many shares 850,820 is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Cyclacel Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Cyclacel Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Cyclacel Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Cyclacel Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Cyclacel Pharmaceuticals Aktienanalyse

What does Cyclacel Pharmaceuticals do?

Cyclacel Pharmaceuticals Inc was founded in 1996 and is headquartered in Berkeley Heights, New Jersey. The company was established by Dr. David Glover, an experienced biotechnology expert, and Dr. Paul Andrews, an oncology pioneer. Cyclacel Pharmaceuticals is a company specializing in the research and development of cancer drugs. It has two main divisions: clinical drug development and drug discovery. The company's business model is to develop innovative cancer drugs to meet the needs of patients with various types of cancer. The company utilizes an innovative approach by researching and developing cyclin-dependent kinase inhibitors (CDKIs) that aim to exploit the specific vulnerabilities of cancer cells. Cyclacel Pharmaceuticals currently offers four products: Seliciclib, Sapacitabin, CYC065, and CYC140. Seliciclib is a CDKI inhibitor that is currently in clinical development and being studied in a phase 2 trial for advanced cancer patients. Sapacitabin is a CDKI stabilizer that is currently being studied in a phase 3 trial for patients with acute myeloid leukemia (AML). CYC065 is a CDKI inhibitor that is still in preclinical development and currently being tested in drug discovery. CYC140 is another CDKI target that is in preclinical development and aims to eliminate cancer cells. Cyclacel Pharmaceuticals has achieved many significant milestones in its history, including the FDA approval of Seliciclib and Sapacitabin as orphan drugs for the treatment of AML. The company has also formed important partnerships with other pharmaceutical companies to further develop and distribute its drug class. Overall, Cyclacel Pharmaceuticals pursues a promising strategy in the fight against cancer through the research and development of CDKI regulators. Although the company has only a few products on the market, it is well positioned to continue growing and developing innovative drugs that can improve patients' lives. Cyclacel Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Cyclacel Pharmaceuticals's Shares Outstanding

Cyclacel Pharmaceuticals's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Cyclacel Pharmaceuticals’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Cyclacel Pharmaceuticals’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Cyclacel Pharmaceuticals’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Cyclacel Pharmaceuticals stock

How many stocks are there of Cyclacel Pharmaceuticals?

The current number of stocks of Cyclacel Pharmaceuticals is 850,820 undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Cyclacel Pharmaceuticals are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Cyclacel Pharmaceuticals evolved in recent years?

The number of shares of Cyclacel Pharmaceuticals has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Cyclacel Pharmaceuticals as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Cyclacel Pharmaceuticals?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Cyclacel Pharmaceuticals pay?

Over the past 12 months, Cyclacel Pharmaceuticals paid a dividend of 0.15 USD . This corresponds to a dividend yield of about 14.56 %. For the coming 12 months, Cyclacel Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Cyclacel Pharmaceuticals?

The current dividend yield of Cyclacel Pharmaceuticals is 14.56 %.

When does Cyclacel Pharmaceuticals pay dividends?

Cyclacel Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Cyclacel Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cyclacel Pharmaceuticals located?

Cyclacel Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cyclacel Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cyclacel Pharmaceuticals from 8/1/2016 amounting to 0.15 USD, you needed to have the stock in your portfolio before the ex-date on 7/13/2016.

When did Cyclacel Pharmaceuticals pay the last dividend?

The last dividend was paid out on 8/1/2016.

What was the dividend of Cyclacel Pharmaceuticals in the year 2023?

In the year 2023, Cyclacel Pharmaceuticals distributed 0 USD as dividends.

In which currency does Cyclacel Pharmaceuticals pay out the dividend?

The dividends of Cyclacel Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Cyclacel Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Cyclacel Pharmaceuticals

Our stock analysis for Cyclacel Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cyclacel Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.